KA SHUI INT'L (00822) releases annual results, shareholders' share of losses reaches HK$27.907 million, a year-on-year decrease of 54.48%.
Journey International (00822) released its annual results for the year ended December 31, 2025. The group achieved a revenue of HKD 1.464 billion, a decrease of 1.23% year-on-year. The company's attributable loss to equity holders narrowed by 54.48% to HKD 27.907 million, with a basic loss per share of 3.12 HK cents.
KA SHUI INT'L (00822) announced its annual performance for the year ending December 31, 2025. The group achieved a revenue of HK$1.464 billion, a decrease of 1.23% year-on-year; the loss attributable to equity holders of the company was HK$27.907 million, a decrease of 54.48% year-on-year; and the basic loss per share was HK$0.312.
The announcement stated that due to the strong performance of the magnesium alloy division, revenue increased significantly by 34.3% annually, from HK$463 million in 2024 to HK$621 million in 2025. However, with weaker performance in the plastic, aluminum alloy, and other business divisions, the group's overall revenue slightly decreased compared to the previous year.
Related Articles

RITAMIX (01936) announces its performance for 2025. The company's equity holders' share of profits amounted to 9.273 million Malaysian Ringgit, an increase of 12.05% compared to the previous year.

RENHENG ENT (03628) announced its annual performance, with a net profit of HK$13.95 million, an increase of 98.37% year-on-year.

LEON INSPECTION (01586) announced its annual performance, with net profit attributable to shareholders of 38.734 million Hong Kong dollars, a 53.18% decrease compared to the previous year.
RITAMIX (01936) announces its performance for 2025. The company's equity holders' share of profits amounted to 9.273 million Malaysian Ringgit, an increase of 12.05% compared to the previous year.

RENHENG ENT (03628) announced its annual performance, with a net profit of HK$13.95 million, an increase of 98.37% year-on-year.

LEON INSPECTION (01586) announced its annual performance, with net profit attributable to shareholders of 38.734 million Hong Kong dollars, a 53.18% decrease compared to the previous year.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


